Is tezepelumab more than just an anti-eosinophil drug?

Tezepelumab significantly reduces airway eosinophilia, which is the most likely mechanism by which it reduces the risk of asthma exacerbation in patients with moderate–severe asthma, but has little effect on airway hyperresponsiveness to mannitol https://bit.ly/3xnt5sS
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research